ARTICLE | Product Development
How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone
By Stephen Hansen, Director of Biopharma Intelligence
March 18, 2024 10:40 PM UTC


Preclinical data suggest NLRP3 could be an important new target for treating obesity. Among the benefits could be oral dosing with fewer side effects than GLP-1s and an improved cardioprotective profile. But investors shouldn’t expect to see efficacy as quickly for the anti-inflammatory mechanism as observed with incretin-based therapies.
The NLRP3 inflammasome has been implicated as a driver of pathology in a variety of diseases, ranging from cancer to asthma, heart disease and metabolic-associated steatohepatitis (MASH)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651740/treating-obesity-by-quelling-inflammation-in-the-brain